The Molecular and Cellular Immunology Core: The Emory Transplant Center and this Consortium benefits from an integrated approach to performing nonhuman primate (NHP) transplant tolerance research. The hub of this integration is the integrated Molecular and Cellular Immunology Core (MClC), which coordinates and streamlines all common assays and procedures, as well as the NHP procurement and typing needs for all members of the ETC. The MClC is comprised of five interacting elements: (1) The MHC Immunogenetics and Typing Core. (2) The Flow Cytometry Core. (3) The NHP Histopathology Core. (4) The Molecular Immunology and Virology Core and (5) The Functional Protective Immunity Core. Each Core addresses a critical need for the conduct of the complex experiments that are proposed in each of the projects and promotes collaboration between investigators. As such, the development of these integrated services has significantly increased the efficiency and the rigor with which our group is able to execute complex NHP transplantation tolerance research.
Renal transplantation represents first-line therapy for patients with end-stage renal disease, with over 16,000 transplants being performed each year. While most patients initially do well post-transplant, they almost invariably face significant toxicities, including off-target complications of non-specific immunosuppression and the constant risk of chronic rejection. The ultimate answer for all of these issues is immune tolerance induction. This application seeks to define clinically-relevant tolerance-induction strategies, which could improve the lives of tens of thousands of transplant patients each year.
|Kean, Leslie S; Turka, Laurence A; Blazar, Bruce R (2017) Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. Immunol Rev 276:192-212|
|Kwun, Jean; Manook, Miriam; Page, Eugenia et al. (2017) Crosstalk Between T and B Cells in the Germinal Center After Transplantation. Transplantation 101:704-712|
|Manook, M; Kwun, J; Burghuber, C et al. (2017) Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation. Am J Transplant 17:2055-2064|
|Mathews, D V; Wakwe, W C; Kim, S C et al. (2017) Belatacept-Resistant Rejection Is Associated With CD28+ Memory CD8 T Cells. Am J Transplant 17:2285-2299|
|Samy, K P; Anderson, D J; Lo, D J et al. (2017) Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model. Am J Transplant 17:1193-1203|
|Kwun, Jean; Burghuber, Christopher; Manook, Miriam et al. (2017) Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates. Blood Adv 1:2115-2119|
|Tkachev, Victor; Furlan, Scott N; Watkins, Benjamin et al. (2017) Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med 9:|
|Kwun, Jean; Burghuber, Christopher; Manook, Miriam et al. (2017) Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients. J Am Soc Nephrol 28:1991-1996|
|Kim, S C; Wakwe, W; Higginbotham, L B et al. (2017) Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection. Am J Transplant 17:1182-1192|
|Schroder, Paul M; Ezekian, Brian; Ford, Mandy et al. (2017) Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. Front Immunol 8:1615|
Showing the most recent 10 out of 66 publications